Rautio A
Biomed Pharmacother. 1984;38(4):199-204.
Medroxyprogesterone acetate (MPA) elimination rate was investigated in 25 patients with primary biliary cirrhosis, alcoholic cirrhosis and fatty liver. The serum and urine concentrations of MPA were measured by RIA after a single oral administration of the drug. Biochemical liver tests and antipyrine kinetics were determined as indicators of the liver function. The antipyrine test, a reflector of the activity of hepatic drug-metabolizing enzyme system, was impaired only in alcoholics. The results demonstrate that the elimination rate of MPA is reduced in subjects with alcoholic cirrhosis, whereas the values of the patients with fatty liver and primary biliary cirrhosis are in the normal range. The findings show that the MPA elimination is impaired only in cases with far advanced liver disease.
对25例原发性胆汁性肝硬化、酒精性肝硬化和脂肪肝患者的醋酸甲羟孕酮（MPA）消除率进行了研究。单次口服该药物后，采用放射免疫分析法测定血清和尿液中MPA的浓度。将生化肝功能检查和安替比林动力学作为肝功能指标进行测定。安替比林试验作为肝脏药物代谢酶系统活性的反映指标，仅在酒精性肝硬化患者中受损。结果表明，酒精性肝硬化患者的MPA消除率降低，而脂肪肝和原发性胆汁性肝硬化患者的数值在正常范围内。研究结果显示，仅在晚期肝病患者中MPA消除受损。
